EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation

Maria Cassola, Omar Junior Leal Niebla

BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences · 13.05.2026

DOI: 10.70099/bj/2026.03.02.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, online erschienen am 13.05.2026. Verfasst von Maria Cassola und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcineurin inhibitors (CNIs), particularly tacrolimus, remain the cornerstone of maintenance immunosuppression in kidney transplantation. However, their long-term use is limited by dose-dependent nephrotoxicity, metabolic complications including new-onset diabetes after transplantation (NODAT), neurotoxicity, and progressive allograft dysfunction. These limitations have driven the search for alternative strategies capable of preserving graft function while minimizing toxicity. Tegoprubart (AT-1501) is a next-generation, humanized, Fc-silent monoclonal antibody targeting CD40 ligand (CD40L), a critical mediator of T cell–B cell costimulatory signaling. By selectively blocking the CD40/CD40L pathway, tegoprubart inhibits germinal center formation, suppresses B cell activation, and prevents donor-specific antibody (DSA) development, thereby addressing both cellular and humoral alloimmune responses. Importantly, Fc engineering eliminates Fcγ receptor binding, mitigating the platelet activation and thromboembolic complications observed with earlier anti-CD40L therapies. Preclinical studies in non-human primate models and emerging clinical data, including results from the BESTOW Phase 1b/2 program, demonstrate that tegoprubart-based regimens are associated with preserved or improved renal function, low rates of acute rejection, absence of NODAT, and a favorable safety profile. Comparative analyses suggest potential advantages over tacrolimus-based regimens and CD40-targeting approaches, particularly in maintaining long-term graft integrity. Despite these promising findings, current evidence remains limited by small sample sizes, short follow-up, and early-phase trial designs. Ongoing Phase 3 studies are required to confirm long-term efficacy, safety, and applicability across broader transplant populations. Tegoprubart represents a promising CNI-free immunosuppressive strategy with the potential to redefine maintenance therapy in kidney transplantation by improving long-term outcomes while reducing treatment-related toxicity.

Zitieren

APA

Cassola, M., & Niebla, O. J. L. (2026). Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. https://doi.org/10.70099/bj/2026.03.02.10

Vancouver

Cassola M, Niebla OJL. Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. 2026. doi:10.70099/bj/2026.03.02.10

BibTeX
@article{Cassola2026,
  author = {Cassola, Maria and Niebla, Omar Junior Leal},
  title = {Tegoprubart and the CD40L Pathway: Promise and Remaining Questions in CNI-Free Kidney Transplantation},
  journal = {BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences},
  year = {2026},
  doi = {10.70099/bj/2026.03.02.10}
}
Kostenlos starten →